Immuneering Corporation.
IMRX.US | Research and experimental development on natural sciences and engineering
Immuneering Corporation is a biopharmaceutical company focused on developing novel therapies for oncology and other diseases. They utilize a proprietary Disease Cancelling Technology platform to identify and develop drug candidates that disrupt cancer cell networks and address unmet medical needs. T...Show More
Better Health for All
30
Immuneering Corporation is a clinical-stage biopharmaceutical company focused entirely on developing novel oncology therapies. Its drug pipeline focuses on cancer medicines, aligning with priority diseases in the Access to Medicine Index.
1
The lead candidate, Atebimetinib (IMM-1-104), is in Phase 2a clinical trials for pancreatic cancer and other RAS-mutant cancers.
2
Positive data from a Phase 2a trial showed 94% overall survival at 6 months and 72% progression-free survival at 6 months, significantly exceeding the standard of care benchmarks of 67% and 44% respectively.
3
The company has no marketed products, thus no revenue from harmful products.
4
For its clinical trials, IMM-1-104 has demonstrated a favorable tolerability profile with no serious adverse events and no Grade 3+ events in a majority of adverse event categories.
5
The company initiated a Phase 1/2a clinical trial (NCT05585320) in the US and reported no FDA sponsor inspections or monetary losses from legal proceedings related to clinical trials in 2022.
6
IMM-1-104 has received FDA Fast Track designation for first-line and second-line pancreatic cancer.
7
The company does not currently offer expanded access for any product candidates.
8
Fair Money & Economic Opportunity
0
No evidence available to assess Immuneering Corporation on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
Immuneering Corporation's CEO pay ratio in 2024 was approximately 107:1, based on a CEO total compensation of $7,069,657 and median employee compensation of $66,345.
1
The Compensation Committee is fully independent, oversees executive compensation, and monitors decisions.
2
Cash incentive compensation is structured with negative discretion, performance-based stock compensation, a clawback policy, no employment agreements, and no severance agreements.
3
In 2024, 96% of votes approved the executive compensation program, with an average approval of approximately 95% over the last five years.
4
Non-management directors must own shares with a value at least three times their annual cash retainer.
5
The company also provides details on retirement plans and medical programs for employees.
6
Fair Trade & Ethical Sourcing
0
No specific, quantifiable evidence was found in the provided articles to assess Immuneering Corporation against any of the KPIs for Fair Trade & Ethical Sourcing. The articles either explicitly state that no data is provided for the relevant KPIs or discuss general industry trends and regulations not specific to Immuneering's supply chain practices or performance. Information about the company's CROs being GMP certified and regulatory authority inspected, or its internal DEI initiatives and code of conduct, does not provide the specific data points required by the rubric for fair trade certifications, audit frequency, forced labor incidents, traceability, remediation speed, ethical clause coverage, high-risk materials spend, or supplier diversity spend.
1
Honest & Fair Business
-20
Immuneering Corporation has an Ethics Hotline available 24/7 by telephone and online, allowing employees and directors to report violations anonymously.
1
The company prohibits retaliation against those who, in good faith, seek help or report violations.
2
However, there is no evidence of the policy's communication to all staff or the number of cases. The company has not had any financial restatements in the past five years.
3
Immuneering has an Anti-Corruption Compliance Policy from November 2018, which prohibits bribery and corrupt conduct, covers the U.S. Foreign Corrupt Practices Act (FCPA) and U.K. Bribery Act 2010 (UKBA), applies globally to all operations and third parties, prohibits facilitating payments, requires accurate books and records, and includes training and a reporting mechanism.
4
However, the frequency of training and effectiveness metrics are not detailed.
Kind to Animals
-40
Immuneering Corporation utilizes humanized 3D-tumor growth assays and a proprietary, human-aligned 3D tumor modeling platform for preclinical testing.
1
However, the company also conducts preclinical studies using animal models, including female BALB/c nude mice, and generates results across a broad range of animal tumor models.
2
The company's policy prohibits discretionary animal testing, but legal mandates still override alternatives.
No War, No Weapons
0
The provided articles do not contain any specific, concrete data points or information relevant to Immuneering Corporation's involvement in arms manufacturing, military contracts, conflict facilitation, or any related peace initiatives.
1
The articles primarily focus on the company's biopharmaceutical business and general ESG risk ratings, explicitly stating that they do not contain data relevant to 'No War, No Weapons'.
2
Therefore, no KPIs can be scored.
Planet-Friendly Business
0
Immuneering Corporation's 2022 Sustainability Report indicates that packaging CO2 reduction is not applicable or reported because the company does not have a commercial product portfolio.
1
For all other Planet-Friendly Business KPIs, the provided articles explicitly state that no information is available, or they do not contain any relevant data points.
Respect for Cultures & Communities
0
No relevant evidence was found in the provided articles to assess IMRX.US against the 'Respect for Cultures & Communities' ethical value. The articles discuss general pharmaceutical industry news, leadership changes, and medical conditions, but do not contain specific data points related to IMRX.US's engagement with communities, cultural impact, or related initiatives.
Safe & Smart Tech
0
No evidence available to assess Immuneering Corporation on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
The provided articles do not contain any specific quantitative data or information regarding Immuneering Corporation's (IMRX.US) waste management practices, product recyclability, packaging sustainability, recycled content, or any other metrics relevant to the 'Zero Waste & Sustainable Products' ethical value.
1
The reports explicitly state a lack of data for these areas, focusing instead on clinical trial and employee metrics.
2